Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney


Received March 24, 2017; first decision April 10, 2017; revision accepted June 30, 2017.

From the Department of Health Sciences (L.V.W., A.M.E., N. Shrine, C.B., T.B., M.D.T.), and Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre (C.P.N., P.S.B., N.J.S.), University of Leicester, United Kingdom; Department of Epidemiology (A.V., P.J.v.d.M., I.M.N., H. Snieder), Division of Nephrology, Department of Internal Medicine (M.H.d.B., M.A.S.), Interdisciplinary Center Psychopathology and Emotion Regulation (IPCE) (A.J.O., H.R., C.A.H.), Department of Genetics, (M.S.), and Department of Cardiology (P.v.d.H.), University of Groningen, University Medical Center Groningen, The Netherlands; Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Iran (A.V.); Department of Psychiatry, VU University Medical Center, Neuroscience Campus Amsterdam, The Netherlands (R. Jansen); Hebrew SeniorLife, Harvard Medical School, Boston, MA (R. Joehanes); National Heart, Lung and Blood Institute’s Framingham Heart Study, MA (R. Joehanes, A.D.J., M. Larson); Institute of Psychiatry, Psychology and Neuroscience (P.F.O.), and Department of Twin Research and Genetic Epidemiology (M.M., C. Menni, T.D.S.), King’s College London, United Kingdom; Clinical Pharmacology, William Harvey Research Institute (C.P.C., H.R.W., M.R.B., M. Brown, B.M., M.R., P.B.M., M.J.C.) and NIHR Barts Cardiovascular Biomedical Research Unit (C.P.C., H.R.W., M.R.B., M. Brown, P.B.M., M.J.C.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA (L.M.R., F.G., P.M.R., D.I.C.); Department of Epidemiology (G.C.V., A. Hofman, A.G.U., O.H.F.), Genetic Epidemiology Unit, Department of Epidemiology (N.A., B.A.O., C.M.v.D.), and Department of Internal Medicine (A.G.U.), Erasmus MC, Rotterdam, The Netherlands; Department of Biological Psychology, Vrije Universiteit, Amsterdam, EMGO+ Institute, VU University Medical Center, The Netherlands (J.J.H., E.J.d.G., G.W., D.I.B.); Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden (R.J.S., M. Frånberg, A. Hamsten); Centre for Molecular Medicine, Karolinska Universitetssjukhuset, Solna, Sweden (R.J.S., M. Frånberg, A. Hamsten); Estonian Genome Center (T.E., E.O., A. Metspalu), Institute of Molecular Medicine and Translational Medicine (S.S., M. Laan), and Estonian Genome Center (M.P.), University of Tartu, Estonia; Divisions of Endocrinology/Children’s Hospital, Boston, MA (T.E.); Broad Institute of Harvard and MIT, Cambridge, MA (T.E., C.M.L., C.N.-C.); Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (D.E.A., P.N., A. Chakravarti, G.B.E.); The Population Science Branch, Division of Intramural Research, National Heart Lung and Blood Institute (S.-J.H., D.L.), Laboratory of Neurogenetics, National Institute on Aging (M.A.N.); Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute (F.C.), © 2017 American Heart Association, Inc.

Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.117.09438
Guillaume Paré, Alison Patti, Brenda W.J.H. Pennix, Neil Poulter, Peter P. Pramstaller, Olli T. Raitakari, Meixia Ren, Kenneth Rice, Paul M. Ridker, Harriëtte Riese, Samuli Ripatti, Antonieta Robino, Jerome I. Rotter, Igor Rudan, Yasaman Saba, Aude Saint Pierre, Cinzia F. Sala, Anti-Pekka Sarin, Reinhold Schmidt, Rodney Scott, Marc A. Seelen, Denis C. Shields, David Siscovick, Rossella Sorice, Alice Stanton, David J. Stott, Johan Sundström, Morris Swertz, Kent D. Taylor, Simon Thom, Joanna Tzoulaki, Christophe Tzourio, André G. Uitterlinden; Understanding Society Scientific Group*; Uwe Völker, Peter Vollenweider, Sarah Wild, Gonneke Willemsen, Alan F. Wright, Jie Yao, Sébastien Thériault, David Conen, John Attia, Peter Sever, Stéphanie Debette, Dennis O. Mook-Kanamori, Eleftheria Zeggini, Tim D. Spector, Pim van der Harst, Colin N.A. Palmer, Anne-Claire Vergnaud, Ruth J.F. Loos, Ozren Polasek, John M. Starr, Giorgia Girootto, Caroline Hayward, Jaspal S. Kooner, Cecilia M. Lindgren, Veronique Vitar, Niles J. Samani, Jaakko Tuomilehto, Ulf Gyllensten, Paul Knekt, Ian J. Deary, Marina Ciullo, Roberto Eloua, Bernard D. Keavney, Andrew A. Hicks, Robert A. Scott, Paolo Gasparini, Maris Laan, YongMei Liu, Hugh Watkins, Catharina A. Hartman, Veikko Salomaa, Daniela Tonio, and Center for Information Technology (Y.D., P.J.M., Q.T.N.), National Institutes of Health, Bethesda, MD; The Framingham Heart Study, Framingham, MA (S.-J.H., D.L.); The Institute for Translational Genomics and Population Sciences, Department of Pediatrics (X.G., J.Y.), and The Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine (J.I.R.), LABioMed at Harbor-UCLA Medical Center, Torrance, CA; Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland (Z.K., M. Bochud); Swiss Institute of Bioinformatics, Lausanne, Switzerland (Z.K.); Department of Cardiology (S. Trompet, J.W.J.); Department of Gerontology and Geriatrics (S. Trompet), Department of Clinical Epidemiology (R.L.-G., R.d.M., D.O.M.-K.), Department of Molecular Epidemiology (J.D.), and Department of Public Health and Primary Care (D.O.M.-K.), Leiden University Medical Center, The Netherlands; Institute for Community Medicine (A.T.), Department of Internal Medicine B (M.D.), and Interfaculty Institute for Genetics and Functional Genomics (U.V.), University Medicine Greifswald, Germany; DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Germany (A.T., M.D., U.V.); Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany (J.S.R., A. Peters); Cardiovascular Health Research Unit, Department of Medicine (J.C.B., B.M.P.) and Departments of Biostatistics (K.R.), Epidemiology (B.M.P.), and Health Services (B.M.P.), University of Washington, Seattle; Icelandic Heart Association, Kopavogur, Iceland (A.V.S., V. Gudnason); Faculty of Medicine, University of Iceland, Reykjavík, Iceland (A.V.S., V. Gudnason); Department of Clinical Chemistry, Finnlab Laboratories, Tampere, Finland (L.-P.L., T.L.); Department of Clinical Chemistry, Faculty of Medicine and Life Sciences, University of Tampere, Finland (L.-P.L., T.L.); Wellcome Trust Centre for Human Genetics (A. Mahajan, A.G., M. Farrall, T.F., C.M.L., H.W., A.P.M.), and Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom; MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, United Kingdom (N.J.W., J.L., C.L., R.J.F.L., R.A.S., J.H.Z.); Clinical Division of Neurogenetics, Department of Neurology (E.H., R. Schmidt), Institute of Medical Informatics, Statistics and Documentiation (E.H.), and Department of Neurology (H. Schmidt), Medical University Graz, Austria; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics (P.K.J., H.C., R.E., S.W., J.F.W.), Centre for Cognitive Ageing and Cognitive Epidemiology (L.M.L., S.E.H., G.D., A.J.G., D.C.M.L., J.M.S., J.J.D.), Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine (A. Campbell), Generation Scotland, Centre for Genomic and Experimental Medicine (A. Campbell, S.P., C.H.), Department of Psychology (G.D., D.C.M.L., A. Patti, J.D.), Alzheime Scotland Dementia Research Centre (J.M.S.) and Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine (C.H.), University of Edinburgh, Scotland; United Kingdom; Department of Health, Welfare and Health (T.H.), Helsinki, Finland; Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy (M.T., C.M.B., C.F.S., D.T.); Data Tecnica International, Glen Echo, MD (M.A.N.); Medical Genetics, RRCCS-Burlo Garofolo Children Hospital, Trieste, Italy (D.V.G., G.P.); Department of Medical, Surgical and Health Sciences, University of Trieste, Italy (D.V., I.G., M. Brunat, M. Coccia, A. Morgan, G.G., P.G.); Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Bolzano, Italy (E.D.G.M., P.P.P., A.S.S.P.); Department of Human Genetics, University of Tuebingen (T.D.V., E.P.B., R.J.F.L., and Mindich Child health Development Institute (R.J.F.L.), Icahn School of Medicine at Mount Sinai, New York; Cardiovascular Epidemiology and Genetics, IMIM, and CIBERCV, Barcelona, Spain (J. Marrugat, R.E.); Institute of Medical Genetics and Biophysics A. Buzzati-Traverso, CNR, Napoli, Italy (D.R., T. Nutile, R. Sorice, M. Ciullo); Department of Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin (L.M.L.); UCD Conway Institute, Centre for Proteome Research (L.M.L.), and School of Medicine, Conway Institute (D.C.S.), University College Dublin, Bellfield, Ireland; Department of Immunology, Genetics and Pathology, Uppsala University, Science for Life Laboratory, Sweden (S.E., Å. Johansson, U.G.); Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor (A.U.J., M. Boehnke); NHIR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester United Kingdom (C.P.N., P.S.B., N.J.S.); MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine (J.E.H., V.V., J. Marten, A.F.W., F.J.W.), and Medical Genetics Section, Centre for Genomic and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine (S.E.H.), University of Edinburgh, Western General Hospital, Scotland; United Kingdom; Department of Epidemiology and Biostatistics, School of Public Health (W.Z., E.E., J.C.C., H.G., B.L., I.T., A.-C.V.), MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health (M.-R.J., P.E.), School of Public Health (N.P.), International Centre for Circulatory Health (S. Thom), and National Heart and Lung Institute (P.S.), Imperial College London, United Kingdom; Department of Cardiology, Ealing Hospital, London North West Healthcare NHS Trust, Southall, United Kingdom (W.Z., J.C.C., I.S.K.); Department of Medical Biology, Faculty of Medicine, University of Split, Croatia (T.Z.); Department of Hygiene and Epidemiology, University of Ioannina Medical School, Greece (E.E.); Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Scotland, United Kingdom (N. Shah, A.S.F.D., C.N.A.P.); Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan (N. Shah); National Institute for Health Research Biomedical Research Centre, London, United Kingdom (M.M.); Department of Human Genetics, Wellcome Trust Sanger Institute, United Kingdom (B.P.P., E.Z.); INSERm U 1219, Bordeaux University, France (S.-J.H., D.L.); Bordeaux University, France (G.C., C.T., S.D.); Hunter Medical Research Institute, New Lambton, NSW, Australia (C.O., E.G.H., R. Scott, J.A.); Center for Statistical Genetics, Department of Biostatistics, Ann Arbor, MI (G.A.); Department of Genetics and Molecular Biology, Jiafah University of Medical Sciences, Iran (B.M., S.M.H.C.); Department of Biostatistics, West Australian Population Health Institute, University of Western Australia (J.B., J.H.); PathWest Laboratory Medicine of Western Australia (J.B., J.H.); School of Pathology and Laboratory Medicine (J.B., J.H.), School of Population and Global Health (J.H.), and School of Medicine and Pharmacology (A. James), The University of Western Australia, Nedlands; Imperial College Healthcare NHS Trust, London, United Kingdom (J.C.C., J.I.S.K.); University of Dundee, Ninewells Hospital & Medical School, United Kingdom (J.C.C.); Institute of Genetic Medicine (H.J.C.), and Institute of Health and Society (C. Mamasoula), Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Pathology, Amsterdam Medical Center, The Netherlands (J.J.D.); Department of Numerical Analysis and Computer Science, Stockholm University, Sweden (M. Frånberg); Department of Public Health and Caring Sciences, Uppsala, Sweden (V. Giedraitis); Helmholtz Zentrum München, Deutsches
Abstract—Elevated blood pressure is a major risk factor for cardiovascular disease and has a substantial genetic contribution. Genetic variation influencing blood pressure has the potential to identify new pharmacological targets for the treatment of hypertension. To discover additional novel blood pressure loci, we used 1000 Genomes Project–based imputation in 150 134 European ancestry individuals and sought significant evidence for independent replication in a further 228 245 individuals. We report 6 new signals of association in or near HSPB7, TNXB, LRP12, LOC283335, SEPT9, and AKT2, and provide new replication evidence for a further 2 signals in EFB2 and NFKBIA. Combining large whole-blood gene expression resources totalling 12 607 individuals, we investigated all novel and previously reported signals and identified 48 genes with evidence for involvement in blood pressure regulation that are significant in multiple resources. Three novel kidney-specific signals were also detected. These robustly implicated genes may provide new leads for therapeutic innovation. *(Hypertension. 2017;70:00-00. DOI: 10.1161/HYPERTENSIONAHA.117.09438.)*  

**Key Words:** blood pressure ■ cardiovascular risk ■ complex traits ■ eSNP ■ GWAS ■ hypertension

Forschungszentrum fuer Gesundheit und Umwelt (GmbH), Neuberger, Germany (C.G.); Department of Psychology, School of Social Sciences, Heriot-Watt University, Edinburgh, United Kingdom (A.J.G.); Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging (T.B.H., L.J.L.); Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (A. Hofman); Center For Life-Course Health Research (M.-R.J.), and Biocenter Oulu (M.-R.J.), University of Oulu, Finland; Unit of Primary Care, Oulu University Hospital, Finland (M.-R.J.); National Heart, Lung and Blood Institute, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.D.M.); Department of Clinical Physiology, Tampere University Hospital, Finland (M.K.); Department of Clinical Physiology, Faculty of Medicine and Life Sciences, University of Tampere, Finland (M.K.); Cardiovascular Research Center (S. Kathiresan, C.N.-C.); Center for Human Genetics (S. Kathiresan), and Center for Human Genetic Research (C.N.-C.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (S. Kathiresan, C.N.-C.); Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, United Kingdom (K.T.K.); Department of Public Health, Faculty of Medicine, University of Split, Croatia (I.K., O.P.); Cardiology, Department of Specialties of Medicine, Geneva University Hospital, Switzerland (L. Lin, F.M.G., K.E.D.); Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory (E.L.), Uppsala University, Sweden; Department of Psychiatry, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam; The Netherlands (Y.M., B.W.J.H.P.); School of Molecular, Genetic and Population Health Sciences, University of Edinburgh, Medical School, Teviot Place, Scotland, United Kingdom (A.D.M.); Department of Epidemiology, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.D.M.); Department of Epidemiology, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.D.M.); Department of Epidemiology, Molecular Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston (A.C.M.); British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences (S.P.), and Institute of Cardiovascular and Medical Sciences, Faculty of Medicine (D.J.S.), University of Glasgow, United Kingdom; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland (A. Palotie, S.R., A.-P.S., M.P.); Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada (G.P., S. Thériault); Department of Neurology, General Central Hospital, Bolzano, Italy (P.P.P.); Department of Neurology, University of Lübeck, Germany (P.P.P.); Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Finland (O.T.R.); Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku (O.T.R.); Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China (M.R.); Harvard Medical School, Boston, MA (P.M.R., D.I.C.); Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (A.R.); Institute of Molecular Biology and Biochemistry, Centre for Molecular Medicine, Medical University of Graz, Austria (Y.S., H. Schmidt); INSERM U1078, Etablissement Français du Sang, Brest Cedex, France (A.S.P.); Faculty of Health, University of Newcastle, Callaghan, NSW, Australia (R. Scott, J.A.); John Hunter Hospital, New Lambton, NSW, Australia (R. Scott, J.A.); The New York Academy of Medicine, New York (D.S.); IRCCS Neuromed, Pozzilli, Isernia, Italy (R. Sorice, M. Ciullo); Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland (A.S.); Institute for Translational Genomics and Population Sciences, Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (K.D.T.); Division of Genetic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA (K.D.T.); Department of Public Health (C.T.), and Department of Neurology (S.D.), Bordeaux University Hospital, France; Department of Internal Medicine, Lausanne University Hospital, CHUV, Switzerland (P.V.); Population Health Research Institute, McMaster University, Hamilton Ontario, Canada (D.C.); National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, United Kingdom (J.S.K.); Dasman Diabetes Institute, Kuwait (J.T.); Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia (J.T.); Department of Neurosciences and Preventive Medicine, Danube-University Krems, Austria (J.T.); Division of Cardiovascular Sciences, The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust, United Kingdom (B.D.K.); Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem (Y.M.L.); Kaiser Permanent Washington Health Research Institute, Seattle, WA (B.M.P.); Institute of Physiology, University Medicine Greifswald, Karlburg, Germany (R.R.); Department of Pulmonary Physiology and Sleep, Sir Charles Gardiner Hospital, Nedlands, Western Australia (A. James); Population Health Research Institute, St George’s, University of London, United Kingdom (D.P.S.); Columbia University Medical Center, New York (W.P.); Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, CA (E.L.); Data Science Institute and Lancaster Medical School, Lancaster University, United Kingdom (J.K.); and Department of Biostatistics, University of Liverpool, United Kingdom (A.P.M.).

*A list of contributing authors is given in the online-only Data Supplement.*

This article was sent to Theodore A. Kotchen, Guest Editor, for review by expert referees, editorial decision, and final disposition.

†These authors contributed equally to this work.

The online-only Data Supplement is available with this article at [http://hyper.ahajournals.orglookup/suppl/doi:10.1161/HYPERTENSIONAHA.117.09438/DC1](http://hyper.ahajournals.orglookup/suppl/doi:10.1161/HYPERTENSIONAHA.117.09438/DC1).
G

enetic support for a drug target increases the likelihood of success in drug development,1 and there is clear unmet need for novel therapeutic strategies to treat individuals with hypertension.2 Several large studies have described blood pressure (BP) variant identification by genome-wide and targeted association approaches.3–10 Clinically, the most predictive BP traits for cardiovascular risk are systolic BP (SBP) and diastolic BP (DBP), reflecting roughly the peak and trough of the BP curve, and pulse pressure, the difference between SBP and DBP.20 reflecting arterial stiffness. Using these 3 traits, we undertook a meta-analysis of 150134 individuals from 54 genome-wide association studies (GWAS) of European ancestry with imputation based on the 1000 Genomes Project Phase 1. To minimize reporting of false-positives associations, we sought stringent evidence for significant independent replication in a further 228245 individuals. We further followed up novel and previously reported association signals in multiple large gene expression databases and the largest kidney tissue expression resource currently available. Finally, we searched for enrichment of associated genes in biological pathways and gene sets and identified whether any of the genes were known drug targets or had tool molecules.

Materials and Methods

Studies Stage 1

Results from 54 independent European-ancestry studies, totaling 150134 individuals, were included in the stage 1 meta-analysis: AGES (n=3215), ARIC (n=9402), ASPS (n=828), B58C (n=6458), BHS (n=4492), CHS (n=3264), Citizen study (n=1099), COLAS (n=5404), COROGENE-CTRL (n=1878), CROATIA-Vis (n=945), CROATIA-Split (n=944), CROATIA-Korcula (n=867), EGCUT (n=6395), EGCUT2 (n=1844), EPIC (n=2100), ERF (n=2617), Fenland (n=1357), FHS (n=8096), FINRISK-ctrl (n=861), FINRISK CASE (n=839), FUSION (n=1045), GRAPHIC (n=1010), H2000-Ctrl (n=1078), HealthABC (n=1661), HTO (n=1000), INGI-CARL (n=456), INGI-FVG (n=746), INGI-VB (n=1775), IPM (n=300), KORAS3 (n=1590), KORAS4 (n=3748), LBC1921 (n=376), LBC1936 (n=800), LOLIPOP-EW610 (n=927), MESA (n=2678), MICROs (n=1148), MIGEN (n=1214), NESDA (n=2336), NSPHS (n=1005), NTR (n=1490), PHASE (n=4535), PIVUS (n=945), PROCARDIS (n=1652), SHIP (n=4068), ULSAM (n=1114), WGHS (n=23049), YFS (n=1987), ORCADES (n=1908), RS1 (n=5645), RS2 (n=2152), RS3 (n=3018), TRAILS (n=1262), TRAILS-CC (n=282), and TWINGENE (n=9789). Full study names and general study information is given in Table S1 in the online-only Data Supplement.

Study-Level Genotyping and Association Testing

Three quantitative BP traits were analyzed: SBP, DBP, and pulse pressure (difference between SBP and DBP). Within each study, individuals known to be taking antihypertensive medication had 15 mm Hg added to their raw SBP value and 10 mm Hg added to their individual SBP, DBP, and pulse pressure (difference between SBP and DBP).20 reflecting arterial stiffness. Using these 3 traits, we undertook a meta-analysis of 150134 individuals from 54 genome-wide association studies (GWAS) of European ancestry with imputation based on the 1000 Genomes Project Phase 1. To minimize reporting of false-positives associations, we sought stringent evidence for significant independent replication in a further 228245 individuals. We further followed up novel and previously reported association signals in multiple large gene expression databases and the largest kidney tissue gene expression resource currently available. Finally, we searched for enrichment of associated genes in biological pathways and gene sets and identified whether any of the genes were known drug targets or had tool molecules.

Materials and Methods

Selection of Regions for Follow-Up

For each trait, regions of association were selected by ranking variants by P value, recording the variant with the lowest P value as a sentinel variant and then excluding all variants ±500 kb from the sentinel and reranking the remaining variants. This was undertaken iteratively until all sentinel variants representing 1 Mb regions containing associations with P<10−6 had been identified. To identify additional signals represented by secondary sentinel variants within 500 kb of each of the sentinel variants, GCTA (the Genome-wide Complex Trait Analysis software)21 was used to run conditional analyses (conditioned on the first sentinel variant) on each of the 1 Mb regions using GWAS summary statistics and linkage disequilibrium (LD) information from ARIC. This was done both for putatively novel regions and for regions that had previously been reported. A χ2 test of heterogeneity of effect sizes across the 54 studies was run for each sentinel variant, and those with P<0.05 for heterogeneity were excluded from further follow-up. Variants with P<10−6 after conditioning on the sentinel SNP (novel or known) in the region and for which any attenuation of the −log10 P value was <1.5 fold were also taken forward for replication.

Studies Stage 2

Data from 14 independent studies, totaling 87360 individuals, and the first release of UK Biobank, totaling 140886 individuals, were combined to replicate the findings from stage 1 (ie, totaling 228245 individuals). Stage 2 study details, including full study names, are given in Table S6 and included 3C-Dijon (n=4061), Airwave (n=14023), ASCOT-SC (n=2462), ASCOT-UK (n=3803), BRIGHT (n=1791), GAPP (n=1685), GoDARTs (n=27413), GS-SEFHS (n=9749), HCS (n=2112), JUPITER (n=8718), LifeLines (n=13376), NEO (n=5731), TwinsUK (n=4973), UK Biobank-CMC (n=140886), and UKHLS (n=7462). Analysis was undertaken using the same methods as described for stage 1 studies. UK Biobank-CMC used a newer imputation reference panel than the other studies, and so proxy variants were selected based on minimizing uncertainty in imputation. Association testing was performed using linear regression of the trait residuals onto genotype dosages under an additive genetic model. Methods to account for relatedness within a study were used where appropriate (Table S3). Results for all variants (single nucleotide polymorphisms [SNPs] and insertion/deletion polymorphisms [INDELs]) were then returned to the central analysis group for further quality control checks and meta-analysis.

Stage 1+Stage 2 Meta-Analysis

After meta-analysis of stage 1 and stage 2 results, signals with a P>5×10−8 were excluded. Of the signals with a final P<5×10−8, dosages were used to take into account uncertainty in the imputation. Association testing was performed using linear regression of the trait residuals onto genotype dosages under an additive genetic model. Methods to account for relatedness within a study were used where appropriate (Table S3). Results for all variants (single nucleotide polymorphisms [SNPs] and insertion/deletion polymorphisms [INDELs]) were then returned to the central analysis group for further quality control checks and meta-analysis.
support for independent replication within the stage 2 studies only was sought. Any signals that had \( P<5\times10^{-4} \) and evidence for independent replication in stage 2 alone indicated by \( P<8.2\times10^{-4} \) (Bonferroni correction for 61 tests) were reported as novel signals of association with BP. Any signals that were subsequently reported by other BP GWAS that were accepted for publication during the time this analysis was ongoing, or signals for which independence from another known signal could not be established, were removed from our list of novel signals at this stage (Table S5).

**Genotype and Gene Expression**

We searched for signals of association of genotype with gene expression for the 22 signals (including 8 novel) described in this study in 134 donors. Full details of each data set can be found in the online initiative whole-blood eQTL resource (microarray, \( n=5257 \)), the National Heart, Lung, and Blood Institute SABRe (Systems Approach to Biomarker Research in Cardiovascular Disease) initiative whole-blood eQTL resource (microarray, \( n=5257 \)), NESDA-NTR (microarray, \( n=4896 \)), BIOS (RNAseq, \( n=2116 \)). The whole-blood data from GTEx was based on data from 338 samples. The kidney data set comprised 236 donor kidney samples from 134 donors.\(^{26} \) Full details of each data set can be found in the online Data Supplement. The source transcriptomic renal data as described\(^{26} \) have been deposited in the GeneExpression Omnibus (NCBI) and are accessible online through GEO Series accession number GSE43974.

**LD Lookup**

The 1000 Genomes Project phase 3 release of variant calls was used (February 20, 2015) using 503 subjects of European ancestry.\(^{27} \) The \( r^2 \) between the sentinel SNPs and all other biallelic SNPs within the corresponding 2 Mb area were calculated using the TabiV and PLINK software package (v1.07).\(^{27,28} \) Annotation was performed using the ANNOVAR software package.\(^{27} \)

**Gene-Based Pathway Analysis**

All genes identified in 3 or 4 of the whole-blood eQTL resources above (Table 2) and genes containing a nonsynonymous variant with \( r^2>0.5 \) with the sentinel variant (Table S14) were tested for enrichment of biological pathways and gene ontology (GO) terms using ConsensusPathDB\(^{29} \) using a false discovery rate <5% cutoff. Enriched pathways and GO terms containing genes only implicated by a single BP-associated variant were not reported.

**Network Analysis**

To construct a functional association network, we combined 2 prioritized candidate gene sets into a single query gene set as (1) genes with \( r^2>0.5 \) with the top \( 5\times10^{-4} \) variant (Table S14) were tested for enrichment of biological pathways and gene ontology (GO) terms using ConsensusPathDB\(^{29} \) using a false discovery rate <5% cutoff. Enriched pathways and GO terms containing genes only implicated by a single BP-associated variant were not reported.

**DNase1 Hypersensitivity Overlap Enrichment Across Tissue and Cell Types**

The functional element overlap analysis of the results of GWAS experiments (Forge tool v1.1)\(^{30} \) was used to test for enrichment of overlap of BP SNPs in tissues and cell lines from the Roadmap and ENCODE (Encyclopedia of DNA Elements) projects. All 164 SNPs were entered and 143 were included in the analysis. SNPs from 9 commonly used GWAS arrays were used to select background sets of SNPs for comparison, and 10,000 background repetitions were run. A Z score threshold of \( \geq 2.39 \) (estimated false-positive rate of 0.5%) was used to declare significance.

**Drug–Gene Interactions**

Genes used for pathway and GO enrichment analyses were further investigated for potential druggable or drugged targets using DGIdb (drug gene interaction database).\(^{31} \) Known drug–gene interactions were interrogated across 15 source databases in DGIdb and include all types of interactions. The analysis performed for druggability prediction included all 9 databases exclusively inspecting expert curated data only. We also evaluate genes for known tool compounds using Chembl (www.ebi.ac.uk/chembl/; version 22.1).

**Results**

The stage 1 discovery meta-analysis included 150,134 individuals (Tables S1 through S4 and Figures S1 and S2) and 7,994,604 variants with minor allele frequency >1% and an effective sample size of at least 60% of the total. We used the widely used 2-stage design\(^{32} \) and identified 61 signals in the discovery analysis that were candidates for novel BP signals (\( P<10^{-4} \) for any trait; Table S5). To ensure robustness of signals, we examined BP associations in an additional 228,245 individuals from 15 independent studies for replication, including 140,886 individuals from UK Biobank\(^{19} \) (Table S6). We used the most significant (sentinel) SNP and trait for each locus in replication (61 tests). Twenty-two putatively novel association signals were initially confirmed, showing significant evidence of replication in the independent stage-2 studies (\( P<8.2\times10^{-4} \); Bonferroni correction for 61 tests) and genome-wide significance (\( P<5\times10^{-8} \)) in a meta-analysis across all 378,376 individuals (Table 1 and Table S7). Of these, 14 were subsequently published in 2 other studies\(^{33,34} \), which presented genome-wide significant associations with evidence of replication. A further 2 were highlighted as putative novel signals in one of those studies\(^{33} \) but had not been confirmed by replication. In our study, we report the 6 remaining novel signals, and the 2 previously unconfirmed signals (in EB2 and in NFKBIA), as novel signals. The 8 novel signals included 7 signals at 7 independent loci (Figure S3) and 1 novel independent signal near a previously reported hit near TXNB (Table S8 and Figure S4). The novel signals show both significant evidence of replication in the independent stage-2 studies (\( P<8.2\times10^{-4} \), Bonferroni correction for 61 tests) and genome-wide significance (\( P<5\times10^{-8} \)) in a meta-analysis across all 378,376 individuals. The sentinel variants at all 8 signals were common (minor allele frequency >5%), and the novel secondary signal at TXNB was in high linkage disequilibrium (\( r^2>0.8 \)) with a nonsynonymous SNP. With the exception of rs9710247, which was only significant for association with DBP, all signals were significantly associated (\( P<0.006 \), Bonferroni corrected for 8 tests) with all 3 traits (Table 1 and Table S9).

We next sought to identify which genes might have expression levels that were associated with genotypes of the BP-associated variants reported in this study and others. Strong evidence of an association with expression of a specific gene may provide clues as to which gene(s) might be functionally relevant to that signal. We took the 139 BP association signals...
reported prior to these studies\textsuperscript{17,19} and 22 novel signals of association identified and confirmed in this study and 2 contemporaneous studies\textsuperscript{3–19,24} (Table S10) and searched for evidence of association with gene expression in whole blood (4 studies, total n=12,607; supporting information in the online-only Data Supplement). The 4 blood eQTL data sets were NESDA-NTR,\textsuperscript{40,41} SABRe,\textsuperscript{15} the BIOS resource,\textsuperscript{42} and GTEx\textsuperscript{25} (supporting information in the online-only Data Supplement). The BIOS resource (n=2116) has not previously been used in the analysis of BP associations, and findings from NESDA-NTR and SABRe have been reported for a subset of the previously published signals.\textsuperscript{16,18} For a total of 369 genes, gene expression was associated with the BP SNP in ≥1 data set (Table 2), suggesting robustness of the SNP–gene expression association identified and confirmed in this study and 2 contemporaneous studies\textsuperscript{3–19,24} (Table S10) and searched for evidence of association with gene expression in whole blood (4 studies, total n=12,607; supporting information in the online-only Data Supplement). The 4 blood eQTL data sets were NESDA-NTR,\textsuperscript{40,41} SABRe,\textsuperscript{15} the BIOS resource,\textsuperscript{42} and GTEx\textsuperscript{25} (supporting information in the online-only Data Supplement). The BIOS resource (n=2116) has not previously been used in the analysis of BP associations, and findings from NESDA-NTR and SABRe have been reported for a subset of the previously published signals.\textsuperscript{16,18} For a total of 369 genes, gene expression was associated with the BP SNP in ≥1 data set (Table 2), suggesting robustness of the SNP–gene expression

Table 1. Novel Genome-Wide Significant Signals of Association

<table>
<thead>
<tr>
<th>Variant ID (Noncoded/Coded Allele), Chr:Position, Nearest Gene(s) (Type*), P Value Neff Beta (SE)</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 1+Stage 2</th>
<th>Stage 1+Stage 2 Meta-Analysis P Values for All Traits</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAFTetable</td>
<td>Beta (SE)</td>
<td>Value</td>
<td>Neff</td>
<td>Beta (SE)</td>
</tr>
<tr>
<td>SBP</td>
<td>n1048238 (C/T), 1:16341649, HSPB7 (3’UTR)</td>
<td>0.571</td>
<td>0.366 (0.074)</td>
<td>8.09E-07</td>
</tr>
<tr>
<td></td>
<td>n848309 (proxy) (T/C), 1:16358447</td>
<td>0.567</td>
<td>0.347 (0.072)</td>
<td>1.70E-06</td>
</tr>
<tr>
<td></td>
<td>n185819 (T/C), 6:32,050,067, TNXB (ns)</td>
<td>0.513</td>
<td>0.534 (0.073)</td>
<td>1.93E-13</td>
</tr>
<tr>
<td></td>
<td>n6557876 (C/T), 8:25,900,675, EBF2</td>
<td>0.252</td>
<td>–0.411 (0.084)</td>
<td>8.50E-07</td>
</tr>
<tr>
<td></td>
<td>n35783704 (G/A), 8:105,966,258, LRP12/2ZPM2</td>
<td>0.109</td>
<td>–0.609 (0.121)</td>
<td>4.96E-07</td>
</tr>
<tr>
<td></td>
<td>n73099003 (C/T), 12:53,440,779, LOC283335</td>
<td>0.074</td>
<td>0.768 (0.143)</td>
<td>8.05E-08</td>
</tr>
<tr>
<td></td>
<td>n8904 (G/A), 14:35,871,217, NFXB (3’UTR)</td>
<td>0.375</td>
<td>0.377 (0.078)</td>
<td>6.76E-07</td>
</tr>
<tr>
<td></td>
<td>n57927100 (C/G), 17:75,317,300, SEPT9</td>
<td>0.258</td>
<td>–0.489 (0.086)</td>
<td>1.10E-08</td>
</tr>
</tbody>
</table>

Results from stage 1 and stage 2, and the meta-analysis of stage 1 and stage 2, for all novel genome-wide significant signals of association. P values of association for all 3 traits from stage 1 and stage 2, and the meta-analysis of stage 1 and stage 2, for all novel genome-wide significant signals of association. For intragenic variants, the nearest genes are listed; all other variants are intronic unless indicated otherwise.†Novel signal at previously reported locus.‡Genome-wide significant P values (P<5×10\textsuperscript{−8}).
Table 2. BP-Associated SNPs Associated With Expression of the Same Gene Across 4 or 3 Independent Whole-Blood eQTL Resources and the Kidney Resource

<table>
<thead>
<tr>
<th>Sentinel SNP</th>
<th>Chr</th>
<th>Position</th>
<th>Gene</th>
<th>Blood Data Sets</th>
<th>Top eQTL</th>
<th>Signal in Other Tissue(s) in GTEx</th>
<th>Signal in Kidney</th>
<th>eQTL Signal Previously Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs17367504</td>
<td>1</td>
<td>11862778</td>
<td>CLCN6</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>rs2169137</td>
<td>1</td>
<td>204497913</td>
<td>MDM4</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>rs10926988</td>
<td>1</td>
<td>243483279</td>
<td>SDCCAG8</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs319690</td>
<td>3</td>
<td>47927484</td>
<td>MAP4</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>rs12521868</td>
<td>5</td>
<td>131784393</td>
<td>SLC22A5</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs900145</td>
<td>11</td>
<td>13293905</td>
<td>ARNTL</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1060105</td>
<td>12</td>
<td>123806219</td>
<td>CDK2AP1</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1378942</td>
<td>15</td>
<td>75077367</td>
<td>SCAMP2</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1126464</td>
<td>16</td>
<td>89704365</td>
<td>CHMP1A</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1126464</td>
<td>16</td>
<td>89704365</td>
<td>FANCA</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs12946454</td>
<td>17</td>
<td>43208121</td>
<td>DCAK D</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
</tbody>
</table>

Signal in 4 whole-blood eQTL resources

<table>
<thead>
<tr>
<th>Sentinel SNP</th>
<th>Chr</th>
<th>Position</th>
<th>Gene</th>
<th>Blood Data Sets</th>
<th>Top eQTL</th>
<th>Signal in Other Tissue(s) in GTEx</th>
<th>Signal in Kidney</th>
<th>eQTL Signal Previously Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs17367504</td>
<td>1</td>
<td>11862778</td>
<td>MTHFR</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs871524</td>
<td>1</td>
<td>38411445</td>
<td>FHL3</td>
<td>NYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs871524</td>
<td>1</td>
<td>38411445</td>
<td>SF3A3</td>
<td>NYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs4660293</td>
<td>1</td>
<td>40028180</td>
<td>PABPC4</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>rs6749447</td>
<td>2</td>
<td>169041386</td>
<td>STX39</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs347591</td>
<td>3</td>
<td>11290122</td>
<td>ATG7</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs319690</td>
<td>3</td>
<td>47927484</td>
<td>ZNF589</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs12521868</td>
<td>5</td>
<td>131784393</td>
<td>SLC22A4</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1563788</td>
<td>6</td>
<td>43308383</td>
<td>CRIP3</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10943605</td>
<td>6</td>
<td>79655477</td>
<td>PHIP</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>rs4728142</td>
<td>7</td>
<td>128573967</td>
<td>IRF5</td>
<td>NYYY</td>
<td></td>
<td></td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>rs4728142</td>
<td>7</td>
<td>128573967</td>
<td>TNP03</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2898290</td>
<td>8</td>
<td>11439909</td>
<td>BLK</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2898290</td>
<td>8</td>
<td>11439909</td>
<td>FAM167A</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2898290</td>
<td>8</td>
<td>11439909</td>
<td>FDFT1</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2071518</td>
<td>8</td>
<td>120435812</td>
<td>NOV</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs76452347</td>
<td>9</td>
<td>35906471</td>
<td>TPM2</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10760117</td>
<td>9</td>
<td>123586737</td>
<td>MEGF9</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>rs4494250</td>
<td>10</td>
<td>96563757</td>
<td>HEL LS</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs11191548</td>
<td>10</td>
<td>104846178</td>
<td>NT5C2</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>rs661348</td>
<td>11</td>
<td>1905292</td>
<td>TMNT3</td>
<td>NYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2649044</td>
<td>11</td>
<td>9763969</td>
<td>SBF2</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2649044</td>
<td>11</td>
<td>9763969</td>
<td>SWAP70</td>
<td>YYYY</td>
<td>Y</td>
<td>Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs7129220</td>
<td>11</td>
<td>10350538</td>
<td>ADM</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs7103648</td>
<td>11</td>
<td>47461783</td>
<td>MYBPC3</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3741378</td>
<td>11</td>
<td>65408937</td>
<td>CTSW</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs7302981</td>
<td>12</td>
<td>50537815</td>
<td>LIMA1</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>rs7302981</td>
<td>12</td>
<td>50537815</td>
<td>ATF1</td>
<td>YYYY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
correlation signal and highlighting those genes as potential candidates in genetic BP regulation. Of the 48 genes, 28 have not previously been described in eQTL analyses using BP-associated SNPs, and all were correlated with previously reported BP association signals.

In the kidney data set (TransplantLines), there was an association of gene expression and genotype for 9 SNPs and 13 genes (Table 2 and Figure; Table S12). Nine of the SNP--gene expression associations were also observed in the whole-blood eQTL data sets, suggesting that those signals may not be unique to the kidney. We report 3 signals that were unique to the kidney and not previously reported (C4orf34, HIP2, and ASIC1) and confirm a previously reported kidney eQTL signal for an antisense RNA for PSMD5. The same SNP was also an eQTL for PSMD5 itself in both blood and kidney. ASIC1 encodes the acid sensing ion channel subunit 1, which may interact (and be coexpressed) with ENaC subunits, which mediate transepithelial Na transport in the distal nephron of the kidney. The comparatively small number of signals using kidney tissue (Table 2 and Figure) compared with whole blood could be because of the small sample size. Complete GTEx results are given in Table S13.

For genes implicated by eQTL information from whole blood, we tested for enrichment of biological pathways and GOs. We noted enrichment of the 48 genes implicated by 3 or 4 blood eQTL resources (Table 2) and a further 54 genes containing a nonsynonymous variant with \( r^2 > 0.5 \) with the top SNP (Table S14) in pathways and ontology terms related to actin and striated muscle (Tables S15 and S16). Network analysis using the same genes highlighted further GO terms relating to muscle function, particularly cardiac muscle (Table S17). We tested the overlap of 161 non-HLA BP-associated variants with DNase hypersensitivity sites identified in the Roadmap and ENCODE cell lines and identified an overall enrichment in multiple cell and tissue types, including heart, kidney, and smooth muscle (Figure S5).

We next investigated these genes for potential suitability as drug targets (druggability), known tool compounds, and clinically approved drugs using DGIdb (Table S18). Twelve genes had known drugs, including 4 genes with known antihypertensive drugs. We noted that drugs modulating all but 1 of the 12 drugged targets had a reported influence on BP, either as a primary antihypertensive indication or as a reported side effect of raised BP. Twenty additional genes were predicted druggable, among these 7 genes have known small molecule tool modulators, based on a query of the Chembl database (www.ebi.ac.uk/chembldb/; version 22.1).

### Discussion

Enhanced discovery of BP loci increases the potential targets for therapeutic advances. After major advances in the number of BP loci known over the last years and months, we report 8 novel signals that implicate 5 regions of the genome not previously connected to BP regulation.

Six of the 8 novel signals we report had not previously been reported. Two signals (in EBF2 and NFKBIA) have been suggested previously but without evidence for replication. For these 2 signals, we present, for the first time, stringent evidence of replication, confirming their relevance to BP genetics.

The path from signal to genes is the essential next step toward realizing the therapeutic potential of a genetic locus and understanding the mechanisms of BP regulation. We have used several large eQTL resources as a first step to realize this objective. As expected, we observed that even across eQTL studies of the same tissue, there is limited overlap in experiment-wide significant signals, suggesting either biological variability (differences in the characteristics of the samples or in the methods for extraction and processing of mRNA in each of the studies), technology-specific differences in coverage of genes (use of RNAseq data for the BIOS blood data set and microarray-based expression levels for the kidney and other blood data sets), or the possibility of false-positive results despite stringent within-experiment significance thresholds. We were unable to distinguish these scenarios using the data available to us, but by selecting genes that were significant in at least 3
Wain et al. Novel Blood Pressure Locus and Gene Discovery

resources, and therefore robust to these differences, we identified 48 genes as candidates for further study. These results are limited by the availability of large eQTL resources for whole blood only, which precludes well-powered comparisons across tissue types, particularly, as the origin of BP control is unlikely to be located in the blood. Enrichment and pathway analyses using these genes, and genes containing a correlated functional variant, highlight the potential relevance of muscular tissue and pathways, compatible with a vascular and cardiac origin of BP genetics, extending previous evidence.\textsuperscript{13} We identify several drugged targets in the pathways identified, including 4 existing hypertension targets. Other drugs identified are not suitable candidates for repositioning to hypertension because most were reported in adverse events to raise BP; however, the targets would be valid for investigation using a reverse mechanism, for example, agonism in place of inhibition. We also identified 7 genes with small molecule tool modulators (mainly inhibitory or binding). These molecules and targets might be suitable candidates for further investigation to build a target validation case to support clinical investigation in hypertension.

Among the genes implicated in our eQTL, analyses were several for which there is already some evidence that they are relevant to BP regulation. The intronic SNP rs10926988 was independently associated with expression of \textit{SDCCAG8} in all 4 whole-blood resources. Rare mutations in \textit{SDCCAG8} cause Bardet–Biedl syndrome, which features hypertension. Expression levels of \textit{MYBPC3} were correlated with rs7103648\textsuperscript{15} in the 3 largest blood eQTL resources (ie, SABRe, NESDA-NTR, and BIOS). \textit{MYBPC3} encodes the cardiac isoform of myosin-binding protein C, which is expressed in heart muscle, and mutations in \textit{MYBPC3} are known to cause familial hypertrophic cardiomyopathy.\textsuperscript{45}

This study has several limitations. Given the nature of statistical power for genome-wide association analyses, the sample size is limited, even though this is one of the largest efforts in BP GWAS undertaken to date. The study would clearly have benefited from the availability of larger eQTL resources on multiple tissues in sample sizes even larger than those available today. Our analyses were limited to \textit{cis} signals, and future analyses, with larger sample sizes, might also consider \textit{trans} signals.

\section*{Perspectives}

Our study reports robust novel BP association signals and reports new candidate BP genes, contributing to the transition from variants to genes to explain BP variation. These genes now require further functional validation to establish their potential as drug targets. Our study additionally highlights the challenges of combining and interpreting data from multiple eQTL studies and emphasizes the need for harmonization of data and development of new eQTL resources for multiple tissue types.

In summary, our study reports novel BP association signals and reports new candidate BP genes, contributing to the transition from variants to genes to explain BP variation.

\section*{Acknowledgments}

We thank all the study participants of this study for their contributions. Detailed acknowledgment of funding sources is provided in the Sources of Funding section.

\section*{Author Contributions}

\section*{Secondary Analyses}

Discovery

WGHS: Study phenotyping, P.M. Ridker; Genotyping or analysis, D.I. Chasman and L.M. Rose; Study PI, D.I. Chasman and P.M. Ridker.

RS: Study phenotyping, G.C. Verwoert; Genotyping or analysis, G.C. Verwoert and A.G. Uitterlinden; Study PI, O.H. Franco, A. Hofman, and A.G. Uitterlinden.

NTR: Study phenotyping, E.J. de Geus and G. Willemsen; Genotyping or analysis: J-J. Hottenga, E.J. de Geus, and G. Willemsen; Study PI, D.I. Boomsma and E.J. de Geus.

STR: Study phenotyping, E. Ingelsson; Genotyping or analysis, R.J. Strawbridge and M. Frängeb; Study PI, E. Ingelsson and A. Hamsten.

EGCUT: Genotyping or analysis, T. Esko; Study PI, A. Metspalu.

ARCIC: Genotyping or analysis, D.E. Arking, A.C. Morrison, and P. Nandakumar; Study PI, A. Chakravarti.

FHS: Study phenotyping, D. Levy; Genotyping or analysis, S.-I. Hwang; Study PI, D. Levy.

MESA: Study phenotyping, J.J. Rotter; Genotyping or analysis, W. Palmas, X. Guo, J.J. Rotter, J. Yao; Study PI, W. Palmas.

B5SC: Study phenotyping, D.P. Strachan; Genotyping or analysis, D.P. Strachan; Study PI, D.P. Strachan.

COLAUS: Study phenotyping, P. Vollenweider; Genotyping or analysis, M. Bochud and Z. Kutalik; Study PI, P. Vollenweider.

PROSPER: Study phenotyping, J.W. Jukema and D.J. Stott; Genotyping or analysis, S. Trompet and J. Deelen; Study PI, J.W. Jukema.

BHS: Study phenotyping, A. James; Genotyping or analysis, N. Shrine, J. Hui, and I. Bellby.

SHIP: Study phenotyping, M. Dörr; Genotyping or analysis, A. Teumer, M. Dörr, and U. Volker; Study PI, R. Rettig.

KORA S4: Genotyping or analysis, J.S. Reed; Study PI, A. Peters.

CHS: Study phenotyping, B.M. Psaty; Genotyping or analysis, J.C. Bis, K. Rice, and K.D. Taylor; Study PI, B.M. Psaty.

AGE-S REJKYAVIK: Genotyping or analysis, A.V. Smith; Study PI, V. Gudnason, T.B. Harris, and J.J. Launer.

ERF: Study phenotyping, C.M. van Duijn and B.A. Oostra; Genotyping or analysis, N. Amin; Study PI, C.M. van Duijn and B.A. Oostra.

NESDA: Study phenotyping, B.W.J.H. Penninx; Genotyping or analysis, I.M. Nolte and Y. Milanesch; Study PI, H. Snieder and B.W.J.H. Penninx.

YFS: Study phenotyping, T. Lehtimäki, M. Kähönen, and O.T. Raitakari; Genotyping or analysis, T. Lehtimäki, L.-P. Lyytikäinen, M. Kähönen, and O.T. Raitakari; Study PI, T. Lehtimäki, M. Kähönen, and O.T. Raitakari.

EPIC: Genotyping or analysis, N.J. Wareham; Study PI, J.H. Zhao.

ASPS: Study phenotyping, R. Schmidt; Genotyping or analysis, H. Schmidt, E. Hofer, Y. Saba, and R. Schmidt; Study PI, H. Schmidt and R. Schmidt.


FINRISK (COROGENE_CTRL): Study phenotyping, P. Joussilahit; Genotyping or analysis, K. Kristiansson and A.P. Sarin; Study PI, M. Perola and P. Joussilahit.

INGI-VB: Study phenotyping, C.F. Sala; Genotyping or analysis, M. Traglia, C.M. Barbieri, and C.F. Sala; Study PI, D. Toniole.

FINRISK_PREDICT_CVD: Study phenotyping, V. Salomaa and A.S. Halvulinna; Study PI, V. Salomaa, A. Palotie, and S. Ripatti.

TRAILS: Study phenotyping, H. Riese; Genotyping or analysis, P.J. van der Most; Study PI, C.A. Hartman and A.J. Oldchinkel.

PROCARDIS: Study phenotyping, A. Goel; Genotyping or analysis, A. Goel; Study PI, H. Watkins, and M. Farrall.

HABC: Study phenotyping, Y. Liu and T.B. Harris; Genotyping or analysis, M.A. Nalls; Study PI, Y. Liu and T.B. Harris.

KORA S3: Study phenotyping, C. Gieger; Genotyping or analysis, S. Söber, C. Gieger, and E. Org; Study PI, M. Laan.

INGI-FVG: Genotyping or analysis, D. Vuckovic, M. Brumat, and M. Cocca; Study PI, P. Gasparini.

Fenland: Study phenotyping, R.A. Scott, J. Luan, C. Langenberg, and N.J. Wareham; Genotyping or analysis, R.A. Scott, J. Luan, C. Langenberg, and N.J. Wareham; Study PI, R.A. Scott, C. Langenberg, and N.J. Wareham.

MICROS: Genotyping or analysis, A.A. Hicks, F. Del Greco M., and A. Saint Pierre; Study PI, F. Del Greco M. and P.P. Pramstaller.

HTO: Study phenotyping, B.D. Keavney; Genotyping or analysis, B.D. Keavney, K.L. Ayers, and C. Mamasoula; Study PI, B.D. Keavney and H.J. Cordell.

MIGEN: Study phenotyping, R. Eloussa, J. Marrugat, S. Kathiresan, and D. Siscovick; Genotyping or analysis, R. Eloussa, S. Kathiresan, and D. Siscovick; Study PI, S. Kathiresan.

ULTSAM: Study phenotyping, V. Giedraitis and E. Ingelsson; Genotyping or analysis, A.P. Morris and A. Mahajan; Study PI, A.P. Morris, V. Giedraitis, and E. Ingelsson.

Cilento study: Study phenotyping, R. Sorice; Genotyping or analysis, D. Ruggiero, and T. Nutile; Study PI, M. Ciullo.

LBC1936: Study phenotyping, I.J. Deary and A.J. Gw; Genotyping or analysis, I.M. Lopez, G. Davies, and A.J. Gw; Study PI, I.J. Deary.


NSPHS: Genotyping or analysis, S. Enroth and Å. Johansson; Study PI, U. Gyllensten.

FUSION: Genotyping or analysis, A.J. Jackson; Study PI, J. Tuomilehto, M. Boehnke, and E. Collins.


CROATIA_Vis: Study phenotyping, I. Rudan; Genotyping or analysis, V. Vitart and J.F. Huffman; Study PI, V. Vitart and I. Rudan.

PIVUS: Study phenotyping, L. Lind and J. Sundström; Genotyping or analysis, C.M. Lindgren and A. Mahajan; Study PI, C.M. Lindgren, L. Lind, and J. Sundström.

LOLIPOP: Study phenotyping, J.S. Kooper and J.C. Chambers; Genotyping or analysis, J.S. Kooper, W. Zhang, J.C. Chambers, and B. Lehner; Study PI, J.S. Kooper and J.C. Chambers.

CROATIA_Korcula: Genotyping or analysis, C. Hayward and J. Martens; Study PI, C. Hayward and A.F. Wright.

INGI-CARL: Study phenotyping, G. Girotto; Genotyping or analysis, I. Gandin, A. Morgan, and A. Robino.

LBC1921: Study phenotyping, J.M. Starr and A. Pattie; Genotyping or analysis, J.M. Starr, S.E. Harris, D.C.M. Liewald, and A. Pattie; Study PI, J.M. Starr.

CROATIA_SPLIT: Study phenotyping, O. Polasek and I. Kolcic; Genotyping or analysis, O. Polasek and T. Zemunik; Study PI, O. Polasek.

BioMe (formerly IPM): Genotyping or analysis, Y. Lu; Study PI, R.J.F. Loos and E.P. Bowering.

Replication


GoDARTS: Study phenotyping, C.N.A. Palmer and A.S.F. Doney; Genotyping or analysis, C.N.A. Palmer and N. Shah; Study PI, C.N.A. Palmer and A.D. Morris.

Lifelines: Study phenotyping, M.H. de Borst; Genotyping or analysis, M. Swertz; Study PI, P. van der Harst.

TwinUK: Study phenotyping, C. Menni; Genotyping or analysis, M. Mangino and C. Menni; Study PI, T.D. Siscovick.

Airwave Health Monitoring Study: Genotyping or analysis, A.C. Vergnaud, E. Evangelou, H. Gao, and I. Tzoulaki; Study PI, E. Evangelou.

The UK Household Longitudinal Study (UKHLS): Genotyping or analysis, B.P. Prins; Study PI, E. Zeggini.

Resources for Secondary Analyses

eQTL NESDA NTR: Design of secondary analysis, R. Jansen; Computation of secondary analysis, D.I. Boomsma, R. Jansen, and B.W.J.H. Penninx; Study PI, D.I. Boomsma and B.W.J.H. Penninx. eQTL kidney: Study phenotyping, J.J. Damman and M.A. Seelen; Genotyping or analysis, P.J. van der Most; Study PI, H. Snieker. eQTL BIOS: Design of secondary analysis, R. Jansen; Computation of secondary analysis, R. Jansen; Study PI, R. Jansen. SABRe: Study phenotyping, Y. Demirkale, P.J. Munson, and Q.T. Nguyen; Genotyping or analysis, R. Joehanes; Design of secondary analysis, D. Levy; Study PI, D. Levy. ICBP-Sterming Committee


Sources of Funding

This research used the ALICE and SPECTRE High Performance Computing Facilities at the University of Leicester. G.B. Ehret is supported by Geneva University Hospitals, Geneva University, de Reuter Foundation, the Swiss National Foundation project FN 33CM30-124087, and the Fondation pour Recherches Médicales, Geneva.

Airwave: We thank all participants of the Airwave Health Monitoring Study. The study is funded by the UK Home Office (Grant number 780-TETRA) with additional support from the National Institute for Health Research Imperial College Healthcare NHS Trust and Imperial College Biomedical Research Centre.

ARIC: The Atherosclerosis Risk in Communities Study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HLS6376, and R01HL086994; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Funding support for the Genetic Epidemiology of Causal Variants Across the Life Course (CALiCo) program was provided through the NHGRI PAGE program (U01 HG007416). We thank the staff and participants of the ARIC study for their important contributions.

ASCOT: This work was supported by Pfizer, New York, NY, for the ASCOT study and the collection of the ASCOT DNA repository; by Servier Research Group, Paris, France; and by Leo Laboratories, Copenhagen, Denmark. We thank all ASCOT trial participants, physicians, nurses, and practices in the participating countries for their important contribution to the study. In particular, we thank Clare Muckian and David Toomey for their help in DNA extraction, storage, and handling. This work forms part of the research programme of the NHR Cardiovascular Biomedical Research Unit at Barts.

ASPS: The research reported in this article was funded by the Austrian Science Fund (FWF) grant number P20545-P05 and P13180. The Medical University of Graz supports the database of the ASPS. We thank the staff and the participants of the ASPS for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment and Ing Johann Semmler for the technical assistance at creating the DNA bank.

BRIGHT: This work was supported by the Medical Research Council of Great Britain (grant number G09521010D) and by the British Heart Foundation (grant number PG02/128). The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. This work forms part of the research programme of the NHR Cardiovascular Biomedical Research Unit at Barts.

B5SC: We acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. Genotyping for the B5SC-WTCCC subset was funded by the Wellcome Trust grant 076113/B/04/Z. The B5SC-T1DGC genotyping used resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. B5SC-T1DGC GWAS data were deposited by the Diabetes and Inflammation Laboratory, Cambridge Biomedical Research Centre for Medical Research (CMIR), University of Cambridge, which is funded by Juvenile Diabetes Research Foundation International, the Wellcome Trust, and the National Institute for Health Research Cambridge Biomedical Research Centre; the CMIR is in receipt of a Wellcome Trust Strategic Award (079895). The B5SC-GABRIEL genotyping was supported by a contract from the European Commission Framework Programme 6 (018996) and grants from the French Ministry of Research.

CHS: This CHS research was supported by National Heart, Lung, and Blood Institute (NHBLI) contracts HHSN2682012000036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and HHSN26820090009C and NHBLI grants U01HL08295, R01HL087652, R01HL05756, R01HL03612, R01HL120395, and R01HL130114, with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSA grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Cilento study: The Cilento study was supported by the Italian Ministry of Education Universities and Research (Interomics flagship Project, PON03PE_00060_7), Fp6 (Vasoplus-037254), the Assessorato Ricerca Regione Campania, the Fondazione con il SUD (2011-PDR-13), and the Istituto Banco di Napoli-Fondazione to M. Ciullo. We address special thanks to the populations of Cilento for their participation in the study.

COLAUS: The CoLaus study was and is supported by research grants from GlaxoSmithKline (GSK), the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation
(grants 3200B0-105939, 3200B0-118308, 33CSC0-122661, and 33CS30-139468). We thank all participants, involved physicians, and study nurses to the CoLaus cohort.

COROGENE_CTRL: This study has been funded by the Academy of Finland (grant numbers 139635, 129494, 118065, 129322, and 250207), the Orion-Farmos Research Foundation, the Finnish Foundation for Cardiovascular Research, and the Sigrid Juselius Foundation. We are grateful for the THL DNA laboratory for its skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the samples.

CROATIA Studies: The CROATIA-Vis, CROATIA-Korcula, and CROATIA-Split studies in the Croatian islands of Vis and Korcula and mainland city of Split were supported by grants from the Medical Research Council (UK); the Ministry of Science, Education, and Sport of the Republic of Croatia (grant number 216-1080315-0302); the European Union framework program 6 European Special Populations Research Network project (contract LSHG-CJ-2006-018947); the European Union framework program 7 project BBMRI-LPC (FP7 313010); and the Croatian Science Foundation (grant 8875). The CROATIA studies acknowledge the invaluable contributions of the recruitment teams (including those from the Institute of Anthropological Research in Zagreb) in Vis, Korcula, and Split, the administrative teams in Croatia and Edinburgh, and the people of Vis, Korcula, and Split. SNP genotyping of the CROATIA-Vis samples was performed by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh, Scotland. SNP genotyping for CROATIA-Korcula was performed by Helmholtz ZentrumMünchen, GmbH, Neuherberg, Germany. The SNP genotyping for the CROATIA-Split cohort was performed by AROS Applied Biotechnology, Aarhus, Denmark.

ERF: The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme “Quality of Life and Management of the Living Resources” of 5th Framework Programme (no.QLG2-CT-2002-01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-REFBR 047.017.043).

Exome sequencing analysis in ERF was supported by the ZonMW grant (project 91111025). Najaf Amin is supported by the Netherlands Brain Foundation (project number F2013(1)-28). We are grateful to all study participants and their relatives, general practitioners, and neurologists for their contributions and to P. Vernaart for her help in genealogy, J. Veerse for the supervision of the laboratory work, and P. Snijders for his help in data collection.

Fenland: J. Luan, C. Langenberg, R.A. Scott, and N.J. Wareham acknowledge support from the Medical Research Council (MC_U106179471 and MC_UU_120151). The Fenland Study is funded by theWellcome Trust and the Medical Research Council (MC_U106179471). We are grateful to all the volunteers for their time and help and to the General Practitioners and practice staff for assistance with recruitment. We thank the Fenland Study Investigators, Fenland Study Co-ordination team and the Epidemiology Field, Data and Laboratory teams. We further acknowledge support from the Medical Research Council (MC_UU_120151).

FHS: The National Heart, Lung and Blood Institute’s Framingham Heart Study is supported by contract N01-HC-25195. This study was also funded by the Academy of Finland (grant numbers 139635, 129494, 118065, 129322, 250207, and 269517), the Orion-Farmos Research Foundation, the Finnish Foundation for Cardiovascular Research, and the Sigrid Juselius Foundation. We are grateful for the THL DNA laboratory for its skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the samples.

FUSION: Support for FUSION was provided by National Institutes of Health (NIH) grants R01-DK062370 (to M. Boehnke) and intramural project number ZIA-HG000024 (to F. Collins). Genome-wide genotyping was conducted by the Johns Hopkins University Genetic Resources Core Facility SNP Center at the Center for Inherited Disease Research (CIDR), with support from CIDR NIH contract no. N01-HG-65403.

GAPP study: The GAPP study was supported by the Liechtenstein Government, the Swiss National Science Foundation, the Swiss Heart Foundation, the Swiss Society of Hypertension, the University of Basel, the University Hospital Basel, the Hanela Foundation, Schiller AG, and Novartis.

GS:SFHS: Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR/03006). Genotyping of the GS:SFHS samples was performed by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland, and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “Strengthening Resilience and Depression Longitudinally” (STRADL) Reference 104036/Z/14/Z). Ethics approval for the study was given by the NHS Tayside committee on research ethics (reference 05/S1401/89). We are grateful to all the families who took part, the general practitioners, and the Scottish School of Primary Care for their help in recruiting them and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants, and nurses.

GoDARTS: GoDARTS was funded by The Wellcome Trust (072960/Z/03/Z, 084726/Z/08/Z, 084727/Z/08/Z, 085475/Z/08/Z, and 058475/B/08/Z) and as part of the EU IMI-SUMMIT program. We acknowledge the support of the Health Informatics Centre, University of Dundee, for managing and supplying the anonymized data and NHS Tayside, the original data owner. We are grateful to all the participants who took part in the GoDARTS study, to the general practitioners, to the Scottish School of Primary Care for their help in recruiting the participants, and to the whole team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses.

GRAPHIC: The GRAPHIC Study was funded by the British Heart Foundation (BH/HRG/2000008). C.P. Nelson and N.J. Samani are supported by the British Heart Foundation, and N.J. Samani is an NIHR Senior Investigator. This work falls under the portfolio of research supported by the NIHR Leicester Cardiovascular Biomedical Research Unit.

H2000: The Health 2000 Study was funded by the National Institute for Health and Welfare (THL), the Fiminh Centre for Pensions (ETK), the Social Insurance Institution of Finland (KELA), the Local Government Pensions Institution (KEVA), and other organizations listed on the website of the survey (http://www.terveys2000.fi). We are grateful for the THL DNA laboratory for its skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the GenMets subcohort.

HABC: The Health ABC Study was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106 and, in part, by the NIA Intramural Research Program. The genome-wide association study was funded by NIA grant 1R01AG032908-01A1 to Wake Forest University Health Sciences, and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to the Johns Hopkins University, contract number HHSN268200782096C. This study used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov).

HILD: The study was funded by the Wellcome Trust, Medical Research Council, and British Heart Foundation We thank all the families who participated in the study.

ING-VI: The ING-Val Borbera population is a collection of 1664 genotyped samples collected in the Val Borbera Valley, a geographically isolated valley located within the Appennine Mountains in Northwest Italy. The valley is inhabited by ≈3000 descendants from the original population, living in 7 villages along the valley and in the mountains. Participants were healthy people aged 18 to 102 years who had at least one grandfather living in the valley. The study plan and the informed consent form were reviewed and approved by the institutional
review boards of San Raffaele Hospital in Milan. The research was supported by funds from Compagnia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 2008 and CCM 2010, PRIN 2009, and Telethon, Italy, to D. Tonio. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. We thank the inhabitants of the VB who made this study possible, the local administrations, the MD of the San Raffaele Hospital, and Prof Clara Camaschella for clinical data collection. We also thank Fiammetta Viganò for technical help, Corrado Masciullo and Massimiliano Cocca for building and maintaining the analysis platform.

INGI-CARL: Italian Ministry of Health RF2010 to P. Gasparini and RC2008 to P. Gasparini.

INGI-FVG: Italian Ministry of Health RF2010 to P. Gasparini and RC2008 to P. Gasparini.

JUPITER: Genetic analysis in the JUPITER trial was funded by a grant from AstraZeneca (D.J. Chasman and P.M. Ridker, Co-Pis).

KORA S3: KORA S3 500K blood pressure project was supported by Estonian Research Council, grant IUT34-12 (for M. Laan). The KORA Augsburg studies have been financed by the Helmholt Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany, and supported by grants from the German Federal Ministry of Education and Research (BMBF). The KORA study group consists of H.-E. Wichmann (speaker), A. Peters, C. Meisinger, T. Ilig, R. Holle, J. John, and coworkers who are responsible for the design and conduct of the KORA studies. Part of this work was financed by the German National Genome Research Network (NGFN-2 and NGFNPlus:01GS0823) and supported within the German Center of Health Sciences (MC Health) as part of LMUinnovative.

LBC1921: Phenotype collection in the Lothian Birth Cohort 1921 was supported by the UK’s Biotechnology and Biological Sciences Research Council (BBB SRC), The Royal Society, and The Chief Scientist Office of the Scottish Government. Genotyping was funded by the BBB SRC. The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBB Src and Medical Research Council (MRC) is gratefully acknowledged. We thank the Lothian Birth Cohort 1921 participants and team members who contributed to these studies.

LBC1936: Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age UK (The Disconnected Mind project). Genotyping was funded by the BBB SRC. The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBB SRC and Medical Research Council (MRC) is gratefully acknowledged. We thank the Lothian Birth Cohort 1936 participants and team members who contributed to these studies.

Lifelines Cohort Study: The Lifelines Cohort Study and generation and management of GWAS genotype data for the Lifelines Cohort Study is supported by the Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, Leiden University Medical Center, and National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand Opportunity grants IRC2 MH089951 and IRC2 MH089995). Part of the genotyping and analyses were funded by the National Institutes of Health, Computing was supported by BiG Grid, the Dutch e-Science Grid, which is financially supported by NWO.

NSPHS: The Northern Swedish Population Health Study (NSPHS) was funded by the Swedish Medical Research Council (Project Number K2007-66X-20270-01-3, 2011–2015, 2012–2018, and 2011–2015), the Foundation for Scientific Research (SSF). NSPHS as part of EUROSPAN (European Special Populations Research Network) was also supported by the European Commission FP6 STRP grant number (01947) (LSHG-CT-0601947). This work has also been supported by the Swedish Society for Medical Research (SSMF) and the Swedish Medical Research Council (No. 2015-01327). We are grateful for the contribution of district nurse Svea Henrix for data collection and Inger Jonasson for logistics and coordination of the health survey. We also thank all the participants from the community for their interest and willingness to contribute to this study.

NTR: Funding was obtained from the Netherlands Organization for Scientific Research (Geestkracht program grant 10-000-1002), the Center for Medical Systems Biology (CSMB, NOW Genomics), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL), VU University’s Institutes for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam, Amsterdam University Medical Center Groningen, Leiden University Medical Center, and National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand Opportunity grants IRC2 MH089951 and IRC2 MH089995). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by BI Grid, the Dutch e-Science Grid, which is financially supported by NWO.

NSPHS: The Northern Swedish Population Health Study (NSPHS) was funded by the Swedish Medical Research Council (Project Number K2007-66X-20270-01-3, 2011–2015, 2012–2018, and 2011–2015), the Foundation for Scientific Research (SSF). NSPHS as part of EUROSPAN (European Special Populations Research Network) was also supported by the European Commission FP6 STRP grant number (01947) (LSHG-CT-0601947). This work has also been supported by the Swedish Society for Medical Research (SSMF) and the Swedish Medical Research Council (No. 2015-01327). We are grateful for the contribution of district nurse Svea Henrix for data collection and Inger Jonasson for logistics and coordination of the health survey. We also thank all the participants from the community for their interest and willingness to contribute to this study.

NTR: Funding was obtained from the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organisation for Health Research and Development (ZonMW) grants 904-61-090, 985-10-022, 904-61-193, 480-04-004, 400-05-717, Addiction-31160008, Middelgroot-911-09-032, Spinozapremie 56-464-14192, Biobanking, and Biomolecular Resources Research Infrastructure (BBMRI -NL,}
and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. We are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists.

SHIP: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ0603, 01ZZ0104, MH881/01 and 01ZZ0403), the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of Education and Research (grant no. 03IS0261A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH.

Three-City-Dijon: The 3-City Study is conducted under a partnership agreement among the Institut National de la Santé et de la Recherche Médicale (INSERM), the University of Bordeaux, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseil Régional de Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme “Cohortes et collections de données biologiques.” This work was supported by the National Foundation for Alzheimer’s Disease and Related Disorders, the Institut Pasteur de Lille, the Centre National de Génotypage, and the LABEX (Laboratory of Excellence) program investment for the future) DISTALZ—Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer’s disease. G. Chauhan, C. Tzourio, and S. Debete are supported by a grant from the Fondation Leducq. We thank Philippe Amouyel and the UMR1167 Inserm Univ Littoral Institute Pasteur de Lille for providing the 3C Dijon cohort SNP replication data funded by a grant from the French National Foundation on Alzheimer’s disease and related disorders.

UKHLS: These data are from Understanding Society: The UK Household Longitudinal Study, which is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council. The data were collected by NatCen, and the genome-wide scan data were analyzed by the Wellcome Trust Sanger Institute. The Understanding Society DAC have an application system for genetics data, and all use of the data should be approved by them. The application form is available at https://www.understandingsociety.ac.uk/about/health/data.

TRAILS: This research is part of the Tracking Adolescents’ Individual Lives Survey (TRAILS). Participating centers of TRAILS include the University Medical Center and University of Groningen, the Erasmus University Medical Center Rotterdam, the University of Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in The Netherlands. TRAILS has been financially supported by various grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMW Risk Behavior and Dependence grants 60-60600-97-118; ZonMW Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-061; NWO large-sized investment grant 175.010.2003.005: NWO Longitudinal Survey and Panel Funding 481-08-013 and 481-11-001), the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32), and the participating universities. Statistical analyses were performed on the Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURFsara and financially supported by the Netherlands Scientific Organization (NWO 480-05-003 PF: Posthumoa) along with a supplement from the Dutch Brain Foundation and the VU University Amsterdam.
TwinGene: This project was supported by grants from the Ministry for Higher Education, the Swedish Research Council (M-2005-1112 and 2009–2298), GenoomEUwin (EUQ-LRT-2001-01254; QLG2-CT-2002-01254), NIH grant DK U01-066134, Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellow), European Research Council (ERC Starting Grant), Swedish Diabetes Foundation (grant no. 2013–024), Swedish Research Council (grant no. 2012–1397), and Swedish Heart–Lung Foundation (20120197). We thank the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se) for excellent genotyping. The computations were performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project b2011036.

TwinUK: The study was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007–2013). The study also receives support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London (guystrc-2012-1). We thank the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, quality control, and genotyping; Le Centre National de Génopépide, France, for genotyping; Duke University, NC, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki. Genotyping was also done by CIDR as part of a NEI/NIH project grant.

UK Biobank Cardiometabolic Consortium: The UKB-CMC received support from the British Heart Foundation (grant SP/S3/13/2/10011). This research has been conducted using the UK Biobank Resource under application number 236. H.R. Warren, C.P. Cabrera, and M.R. Barnes were funded by the National Institutes for Health Research (NIHR) as part of the portfolio of translational research of the NIHR Biomedical Research Unit at Barts. M. Ren was funded by the National Institute for Health Research (NIHR) Biomedical Research Unit in Cardiovascular Disease at Barts. M. Ren is recipient from China Scholarship Council (No. 2011632047). B. Mifsud holds an MRC eMedLab Medical Bioinformatics Career Development Fellowship, funded from award MR/L016311/1. P. Elliott was funded by the National Institutes for Health Research (NIHR) Imperial College Health Care NHS Trust and Imperial College London Biomedical Research Centre, the UK Medical Research Council and Public Health England as Director of the MRC-PHE Centre for Environment and Health, and the NIHR Health Protection Research Unit on the Health Effects of Environmental Hazards. Some of this work used computing resources provided by the Medical Research Council–funded UK MEdical Bioinformatics partnership programme (UK MED-BIO) (MR/L01632X/1).

ULSAM: This project was supported by Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellow), European Research Council (ERC Starting Grant), Swedish Diabetes Foundation (grant no. 2013–024), Swedish Research Council (grant no. 2012–1397), and Swedish Heart–Lung Foundation (20120197). The computations were performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project b2011036. Genotyping was funded by the Wellcome Trust under award WT064890. Analysis of genetic data was funded by the Wellcome Trust under award WT098017 and WT090532. A.P. Morris is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (WT098017). We thank the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se) for excellent genotyping.

WGHS: The WGHS is supported by the National Heart, Lung, and Blood Institute (HL043851, HL080467, HL09935) and the National Cancer Institute (CA047988 and UM1CA182913) with collaborative scientific support and funding for genotyping provided by Amgen. YFS: The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117778 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Kuopio, Tampere, and Turku University Hospital Medical Funds (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; and Diabetes Research Foundation Finnish Diabetes Association. The expert technical assistance in the statistical analyses by Irina Lisinen is gratefully acknowledged.

Disclosures

We declare competing financial interests (see corresponding section in the online-only Data Supplement).

References


